dr. kantoff on docetaxel plus androgen deprivation therapy in prostate cancer
Published 7 years ago • 964 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
0:48
dr. kantoff on evolving role of docetaxel in prostate cancer treatment
-
1:16
dr. kantoff on approaches for progressive prostate cancer following androgen blockade
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
6:48
docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer
-
12:11
triggers to initiate androgen-deprivation therapy (adt) in prostate cancer
-
4:15
docetaxel in metastatic prostate cancer
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
4:52
docetaxel in non-metastatic prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
6:13
treatment options in post-docetaxel prostate cancer, part i
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:24
dr. higano on docetaxel for hormone-sensitive prostate cancer
-
5:49
adt plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: systemic review
-
1:32
dr. sandler on docetaxel with hormonal and radiation therapy in prostate cancer
-
6:40
considerations for initiating adt in prostate cancer
-
3:50
considering adt’s role in advanced prostate cancer
-
1:37
dr. caffo discusses enzalutamide/docetaxel combination in frontline mcrpc
-
1:01
dr. agarwal on the advantages of docetaxel in prostate cancer